Spinal Cord Injury Indication Strategy Report 2026: RTN4, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Traumatic Brain Injury Indication Strategy Report 2026: NLRP3, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Subarachnoid Hemorrhage Indication Strategy Report 2026: ETA, Trials and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Neurogene 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Intracerebral Hemorrhage Indication Strategy Report 2026: TLR4, Trials and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Ischemic Stroke Strategy Report 2026: Thrombolysis, NLRP3 and Trials uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Trigeminal Neuralgia Report 2026: Sodium Channels and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Diabetic Peripheral Neuropathy Report 2026: SARM1, Nav1.8 and Trials uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Neuropathic Pain Strategy Report 2026: Nav1.7, Nav1.8 and Trials uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Restless Legs Syndrome Strategy Report 2026: D2/D3 and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Insomnia Indication Strategy Report 2026: Orexin, GABA and Trials uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Narcolepsy Indication Strategy Report 2026: OX2R, H3, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.